Research and Markets: HIV / AIDS - Pipeline Review, Q4 2010 Report Is Complete With Latest Updates, And Special Features on Late-Stage and Discontinued Projects

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/478e97/hiv__aids_pipel) has announced the addition of Global Markets Direct's new report "HIV / AIDS - Pipeline Review, Q4 2010" to their offering.

“HIV / AIDS - Pipeline Review, Q4 2010”

Global Markets Directs, HIV and Aids Pipeline Review, Q4 2010, provides an overview of the HIV and Aids therapeutic pipeline. This report provides information on the therapeutic development for HIV and Aids, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV and Aids. HIV and Aids-Pipeline Review 2010, Q4 2010 is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for HIV and Aids.
A review of the HIV and Aids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the HIV and Aids pipeline on the basis of therapeutic class, route of administration and molecule type.
Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for HIV and Aids.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
Devise corrective measures for pipeline projects by understanding HIV and Aids pipeline depth and focus of HIV and Aids therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Topics Covered:

HIV / AIDS Overview
Therapeutics Development
An Overview of Pipeline Products for HIV / AIDS
HIV / AIDS Therapeutics under Development by Companies
HIV / AIDS Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in HIV / AIDS Therapeutics Development
Universities/Institutes Involved in HIV / AIDS Therapeutics Development
HIV / AIDS Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles Companies
Nov 30, 2010: Argos Initiates Dosing Of Patients In Phase IIb HIV Clinical Trial Of Arcelis
Nov 29, 2010: GeoVax Labs' Strategy Supported By Encouraging Results Of European Therapeutic HIV/AIDS Vaccine Trial
Nov 23, 2010: Idenix Receives $20 Million Milestone Payment From ViiV Healthcare For Initiation Of Phase IIb Trial Of '761
Nov 18, 2010: Bionor Pharma's Vacc-4x Shows Statistically Significant Reduction In Viral Load In Phase IIb HIV Study
Nov 17, 2010: Inovio Pharmaceuticals' HIV DNA Vaccine Achieves Strong T-Cell Immune Responses In Phase I Human Trial
Nov 12, 2010: Inovio Pharmaceuticals To Present HIV Study Update At HVTN Conference
Nov 11, 2010: Theratechnologies Receives FDA Approval For EGRIFTA For Reduction Of Excess Abdominal Fat In HIV-Infected Patients With Lipodystrophy
Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients
Oct 28, 2010: Sequoia Pharmaceuticals Presents In vitro and First-in-human Data Supporting Further Development of SPI-256, A Investigational Protease Inhibitor
Oct 21, 2010: Shionogi-ViiV Initiates Phase III Clinical Program For Investigational Once-Daily HIV Integrase Inhibitor